Subcutaneous ω-Conotoxins Alleviate Mechanical Pain in Rodent Models of Acute Peripheral Neuropathy
Related Experiment Video
Updated: Nov 15, 2025

Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
Md Mahadhi Hasan1, Hana Starobova1, Alexander Mueller1
1Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.
Abstract:
The peripheral effects of ω-conotoxins, selective blockers of N-type voltage-gated calcium channels (CaV2.2), have not been characterised across different clinically relevant pain models. This study examines the effects of locally administered ω-conotoxin MVIIA, GVIA, and CVIF on mechanical and thermal paw withdrawal threshold (PWT) in postsurgical pain (PSP), cisplatin-induced neuropathy (CisIPN), and oxaliplatin-induced neuropathy (OIPN) rodent models. Intraplantar injection of 300, 100 and 30 nM MVIIA significantly (p < 0.0001, p < 0.0001, and p < 0.05, respectively) alleviated mechanical allodynia of mice in PSP model compared to vehicle control group. Similarly, intraplantar injection of 300, 100, and 30 nM MVIIA (p < 0.0001, p < 0.01, and p < 0.05, respectively), and 300 nM and 100 nM GVIA (p < 0.0001 and p < 0.05, respectively) significantly increased mechanical thresholds of mice in OIPN model. The ED50 of GVIA and MVIIA in OIPN was found to be 1.8 pmol/paw and 0.8 pmol/paw, respectively. However, none of the ω-conotoxins were effective in a mouse model of CisIPN. The intraplantar administration of 300 nM GVIA, MVIIA, and CVIF did not cause any locomotor side effects. The intraplantar administration of MVIIA can alleviate incision-induced mechanical allodynia, and GVIA and MVIIA effectively reduce OIPN associated mechanical pain, without locomotor side effects, in rodent models. In contrast, CVIF was inactive in these pain models, suggesting it is unable to block a subset of N-type voltage-gated calcium channels associated with nociceptors in the skin.
Insights
ω-conotoxins MVIIA and GVIA effectively treat mechanical pain in rodent models of postsurgical pain and oxaliplatin-induced neuropathy. These N-type calcium channel blockers showed no adverse locomotor effects, though they were ineffective in cisplatin-induced neuropathy.
Area of Science:
- Pharmacology
- Neuroscience
- Pain Research
Background:
- Peripheral N-type voltage-gated calcium channels (CaV2.2) are implicated in pain signaling.
- The specific efficacy of ω-conotoxins targeting these channels in various pain models remains underexplored.
Purpose of the Study:
- To investigate the peripheral analgesic effects of ω-conotoxins MVIIA, GVIA, and CVIF.
- To evaluate their efficacy in rodent models of postsurgical pain (PSP), cisplatin-induced neuropathy (CisIPN), and oxaliplatin-induced neuropathy (OIPN).
Main Methods:
- Intraplantar administration of ω-conotoxins MVIIA, GVIA, and CVIF in rodent pain models.
- Assessment of mechanical and thermal paw withdrawal thresholds (PWT).
- Evaluation of locomotor activity to determine side effects.
Main Results:
- ω-conotoxin MVIIA significantly alleviated mechanical allodynia in the PSP model.
- MVIIA and GVIA demonstrated significant efficacy in reducing mechanical pain in the OIPN model, with low ED50 values.
- No ω-conotoxins were effective in the CisIPN model.
- No significant locomotor side effects were observed with intraplantar administration.
Conclusions:
- Intraplantar ω-conotoxin MVIIA effectively treats incision-induced mechanical allodynia.
- ω-conotoxins GVIA and MVIIA are effective in managing OIPN-associated mechanical pain without causing locomotor impairment.
- ω-conotoxin CVIF showed no efficacy, suggesting it targets a different subset of CaV2.2 channels than those involved in skin nociception.

